D. Young

Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective

J. Gisbert, G. Girolomoni, K. Gaffney, 2021, Expert opinion on biological therapy.

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]

M. Lech, Trevor R Smith, H. Moyses, 2021, Journal of Crohn's & colitis.

Early real-world effectiveness of ustekinumab for Crohn’s disease

L. Downey, M. McDonnell, R. Harris, 2019, Frontline Gastroenterology.

PMO-20 The IBD biosimilar to biosimilar switching study (iBiSS)

J. Harvey, B. Clancy, R. Harris, 2021, Posters.

Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease: an interview study

Susan Latter, F. Cummings, D. Young, 2022, European journal of hospital pharmacy : science and practice.

Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study

J. Harvey, I. Iria, B. Clancy, 2023, GastroHep.